DEA Places Brexanolone Into Schedule IV
The Drug Enforcement Administration placed the neurosteroid brexanolone into Schedule IV of the Controlled Substances Act, it said. The final rule confirms an interim regulation issued in June that subjected brexanolone to new registration, labeling, recordkeeping, and import and export requirements.
Sign up for a free preview to unlock the rest of this article
Export Compliance Daily combines U.S. export control news, foreign border import regulation and policy developments into a single daily information service that reliably informs its trade professional readers about important current issues affecting their operations.
(Federal Register 01/24/20)